129 related articles for article (PubMed ID: 20394794)
1. The time-dependent change of insulin secretion in schizophrenic patients treated with olanzapine.
Chiu CC; Chen CH; Chen BY; Yu SH; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):866-70. PubMed ID: 20394794
[TBL] [Abstract][Full Text] [Related]
2. The early effect of olanzapine and risperidone on insulin secretion in atypical-naïve schizophrenic patients.
Chiu CC; Chen KP; Liu HC; Lu ML
J Clin Psychopharmacol; 2006 Oct; 26(5):504-7. PubMed ID: 16974193
[TBL] [Abstract][Full Text] [Related]
3. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine.
Chen CH; Chiu CC; Huang MC; Wu TH; Liu HC; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):925-31. PubMed ID: 18082302
[TBL] [Abstract][Full Text] [Related]
4. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients.
Hu S; Yao M; Peterson BS; Xu D; Hu J; Tang J; Fan B; Liao Z; Yuan T; Li Y; Yue W; Wei N; Zhou W; Huang M; Xu Y
Psychopharmacology (Berl); 2013 Nov; 230(1):3-13. PubMed ID: 23559220
[TBL] [Abstract][Full Text] [Related]
5. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Smith RC; Lindenmayer JP; Davis JM; Kelly E; Viviano TF; Cornwell J; Hu Q; Khan A; Vaidhyanathaswamy S
J Clin Psychiatry; 2009 Nov; 70(11):1501-13. PubMed ID: 19814947
[TBL] [Abstract][Full Text] [Related]
6. A prospective study of glucose homeostasis in quetiapine-treated schizophrenic patients by using the intravenous glucose tolerance test.
Chen CH; Lin TY; Chen TT; Chen VC; Lin NC; Shao WC; Lu ML
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):965-9. PubMed ID: 21291941
[TBL] [Abstract][Full Text] [Related]
7. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.
Hosojima H; Togo T; Odawara T; Hasegawa K; Miura S; Kato Y; Kanai A; Kase A; Uchikado H; Hirayasu Y
J Psychopharmacol; 2006 Jan; 20(1):75-9. PubMed ID: 16204328
[TBL] [Abstract][Full Text] [Related]
8. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
Chintoh AF; Mann SW; Lam L; Lam C; Cohn TA; Fletcher PJ; Nobrega JN; Giacca A; Remington G
J Clin Psychopharmacol; 2008 Oct; 28(5):494-9. PubMed ID: 18794643
[TBL] [Abstract][Full Text] [Related]
9. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Lee SY; Park MH; Patkar AA; Pae CU
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Mar; 35(2):490-6. PubMed ID: 21146575
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model.
Chintoh AF; Mann SW; Lam L; Giacca A; Fletcher P; Nobrega J; Remington G
Schizophr Res; 2009 Mar; 108(1-3):127-33. PubMed ID: 19157785
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: results from a 3-month prospective open-label study.
Wampers M; Hanssens L; van Winkel R; Heald A; Collette J; Peuskens J; Reginster JY; Scheen A; De Hert M
Eur Neuropsychopharmacol; 2012 Jan; 22(1):17-26. PubMed ID: 21511441
[TBL] [Abstract][Full Text] [Related]
12. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
13. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone.
Manu P; Correll CU; Wampers M; van Winkel R; Yu W; Shiffeldrim D; Kane JM; De Hert M
Schizophr Res; 2013 Feb; 143(2-3):358-62. PubMed ID: 23231880
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of paliperidone extended release versus oral olanzapine in patients with schizophrenia: a prospective, randomized, controlled trial.
Schreiner A; Niehaus D; Shuriquie NA; Aadamsoo K; Korcsog P; Salinas R; Theodoropoulou P; Fernández LG; Uçok A; Tessier C; Bergmans P; Hoeben D
J Clin Psychopharmacol; 2012 Aug; 32(4):449-57. PubMed ID: 22722501
[TBL] [Abstract][Full Text] [Related]
15. Oral glucose tolerance test performance in olanzapine-treated schizophrenia-spectrum patients is predicted by BMI and triglycerides but not olanzapine dose or duration.
Guina J; Roy S; Gupta A; Langleben DD; Elman I
Hum Psychopharmacol; 2017 Jul; 32(4):. PubMed ID: 28573760
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine induces insulin resistance: results from a prospective study.
Ebenbichler CF; Laimer M; Eder U; Mangweth B; Weiss E; Hofer A; Hummer M; Kemmler G; Lechleitner M; Patsch JR; Fleischhacker WW
J Clin Psychiatry; 2003 Dec; 64(12):1436-9. PubMed ID: 14728104
[TBL] [Abstract][Full Text] [Related]
17. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
[TBL] [Abstract][Full Text] [Related]
18. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
19. Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Smith RC; Lindenmayer JP; Hu Q; Kelly E; Viviano TF; Cornwell J; Vaidhyanathaswamy S; Marcovina S; Davis JM
Schizophr Res; 2010 Jul; 120(1-3):204-9. PubMed ID: 20457512
[TBL] [Abstract][Full Text] [Related]
20. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
Narula PK; Rehan HS; Unni KE; Gupta N
Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
